Rampart Inv Mngmt Lc holds 0.49% or 28,180 shs in its capital. Savings Bank invested in 5,551 shs or 0.1% of the stock.
More notable recent Bristol-Myers Squibb Company (NYSE:BMY) news were published by: Streetinsider.com which released: "Bristol-Myers Squibb (BMY) Reports Positive CHMP Opinion Recommending Sprycel for Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive ALL - StreetInsider.com" on December 17, 2018, also Seekingalpha.com with their article: "I'm Buying Bristol-Myers Down Near 52-Week Lows - Seeking Alpha" published on April 18, 2018, Fool.com published: "Is Bristol-Myers Squibb Company a Buy?" Signaturefd Limited invested in 18,744 shs. Spectrum Asset Mngmt Inc (Nb Ca) holds 0.5% in Bristol-Myers Squibb Company (NYSE:BMY) or 13,550 shs. BMY is hitting $45.12 during the last trading session, after decreased 13.26%.Bristol-Myers Squibb Company is downtrending after having declined 14.97% since January 4, 2018.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, October 25th. 9,800 were accumulated by Ionic Cap Mngmt Ltd Liability Corp. Bristol-Myers Squibb had a net margin of 6.50% and a return on equity of 47.89%. Blb&B Advsr Lc reported 0.73% stake. Tru Commerce Of Virginia Va invested in 24,336 shs. This year's EPS analyst estimate is anticipated to be $0.84. The company has a current ratio of 1.53, a quick ratio of 1.40 and a debt-to-equity ratio of 0.41.
Bristol-Myers pioneered cancer immunotherapy with its Yervoy and later Opdivo, but has come under pressure as Merck & Co's rival treatment Keytruda moved ahead in market share in lung cancer treatment, the most lucrative oncology market.
Bristol-Myers' shares fell sharply as the deal was announced while Celgene's stock rose by around a third. Mcmillion Capital Management Inc. increased its holdings in Bristol-Myers Squibb by 1.4% during the second quarter.
Among 10 analysts covering Bristol-Myers Squibb (NYSE:BMY), 4 have Buy rating, 0 Sell and 6 Hold.
Other institutional investors and hedge funds have also recently modified their holdings of the company. The company rating was maintained by Credit Suisse on Friday, July 27. BMO Capital Markets lifted their price objective on shares of Bristol-Myers Squibb from $55.00 to $58.00 and gave the company a "market perform" rating in a report on Friday, November 16th. On Tuesday, November 27 the firm has "Hold" rating given by Guggenheim. On Wednesday, August 8 the company was upgraded by Atlantic Securities. The firm has "Neutral" rating by Citigroup given on Monday, October 22. Zacks Investment Research downgraded shares of Bristol-Myers Squibb from a "buy" rating to a "hold" rating in a report on Monday, October 1st.
Caforio will continue to serve in those capacities, while two members of Celgene's board will hold spots on Bristol-Myers Squibb's board of directors. It now gets roughly a quarter of its sales from immune-harnessing cancer drug Opdivo, which faces competition from Merck's rival immunotherapy drug Keytruda.
The deal, which would unite the resources of two of the world's pioneers in the treatment of cancer, cardiovascular disease and other maladies, is expected to close in the third quarter of 2019, subject to antitrust and regulatory approval.